PT-112 monotherapy advances to phase 3 trial in metastatic castration-resistant prostate cancer after positive FDA end of ...

American Oncology Institute (AOI), a leading cancer hospital network in South Asia, successfully treated a 61-year-old ...

The American Oncology Institute (AOI) in Guntur has successfully treated a rare and complex case of Myasthenia Gravis ...

PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the ...

Pune: It was indeed a mystery for the doctors at a private hospital in the city. A 23-year-old woman had come in with a ...

Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM TOKYO, /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development ...

How your immune system really ages — research shows aging brings adaptation not decline and reveals ways to maintain immune ...

UbiVac’s DPV-001 induces Development of 1st in-patient generated TCR to Non-Small Cell Lung Cancer’s “Dark Matter” – Targets cancer without apparent toxicity ...

Lusvertikimab selectively inhibits IL-7 but not the thymic stromal lymphopoietin (TSLP) axis, Bourreille told attendees. A ...

AACE released clinical guidelines on the diagnosis, management, and surveillance of tumors related to multiple endocrine neoplasia type 1.

“Thymic carcinoma is a rare cancer with poor prognosis after recurrence, and there is a need for new treatment options. We are working to obtain approval so that Tecentriq that demonstrated favourable ...